Stock Analiz

JNJ vs MRK stock comparison

Johnson & Johnson vs. Merck & Co. · data as of November 13, 2026

Johnson & Johnson (JNJ) has a market value of about $687.9B, Merck & Co. (MRK) about $364.3B. Over their latest twelve months Johnson & Johnson had revenue of $99.3B and Merck & Co. $67.4B.

On our five checks Merck & Co. scores higher: 2.8 out of 5 (average) against 2.6 (average).

By area, the stronger company is Merck & Co. on future growth; Merck & Co. on track record; Johnson & Johnson on financial health.

Johnson & Johnson is cheaper on earnings (P/E 43.4 vs. 150.8), while Merck & Co. grew revenue faster over five years (9.4% vs. 2.7% a year).

Johnson & Johnson leads on 10 of the compared lines and Merck & Co. on 13.

Side by side

JNJMRK
Size and price
Market cap$687.9B$364.3B
Share price$285.75$147.76
Score
Overall score (of 5)2.62.8
Value00
Future growth02
Track record45
Financial health42
Shareholder returns55
Valuation
P/E (TTM)43.4150.8
Forward P/E25.117.6
Price / free cash flow33.424.7
Price / sales6.95.4
EV / EBITDA26.732.5
PEG2.917.10
DCF value vs. price−39%−31%
Business
Revenue$99.3B$67.4B
Net income$16.1B$2.5B
Free cash flow$20.6B$14.7B
Net margin16.2%3.6%
Gross margin (5-yr avg.)69.1%73.4%
ROIC (5-yr avg.)16.6%16.3%
Growth
Revenue growth (1 yr)6.0%1.3%
Revenue growth (5 yrs, per year)2.7%9.4%
EPS growth (5 yrs, per year)14.9%21.2%
Balance sheet and payouts
Net cash (cash minus debt)-$27.4B-$44.1B
Dividend yield1.88%2.30%
Shareholder yield2.8%3.7%
Analysts
Upside to average target−2%+9%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: JNJ TTM to September 27, 2026, MRK TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Johnson & Johnson or Merck & Co.?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Merck & Co. scores 2.8 out of 5 and Johnson & Johnson 2.6; the table shows where each one is stronger.

Is Johnson & Johnson cheaper than Merck & Co.?

On trailing earnings, Johnson & Johnson trades at a P/E of 43.4 and Merck & Co. at 150.8, so Johnson & Johnson is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Which grows faster, Johnson & Johnson or Merck & Co.?

Over five years Merck & Co. grew revenue about 9.4% a year and Johnson & Johnson about 2.7% a year.

Which pays a higher dividend?

Johnson & Johnson yields 1.88% and Merck & Co. 2.30%.

Full Johnson & Johnson analysis → Full Merck & Co. analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.